MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.390
-0.060
-2.45%
After Hours: 2.410 +0.02 +0.84% 17:59 09/22 EDT
OPEN
2.480
PREV CLOSE
2.450
HIGH
2.527
LOW
2.350
VOLUME
785.80K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.980
MARKET CAP
229.46M
P/E (TTM)
-2.6092
1D
5D
1M
3M
1Y
5Y
BRIEF-Point72 Asset Management Reports 5.4% Passive Stake In Avalo Therapeutics As Of Sept. 17
reuters.com · 1d ago
Point72 Asset Management Reports In 13G Filing A 5.4% Stake In Avalo Therapeutics
-SEC Filing
SEC Filing · 1d ago
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 2d ago
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant ...
GlobeNewswire · 2d ago
Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for...
GlobeNewswire · 5d ago
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.
Benzinga · 09/15 16:01
Melco Resorts & Entertainment, Hut 8 Mining, Theravance Biopharma among premarket losers' pack
Nuwellis (NASDAQ:NUWE) -28% after proposes stock offering Theravance Biopharma (NASDAQ:TBPH) -20% after ampreloxetine misses primary endpoint in late-stage orthostatic; on headcount cut to focus on respiratory disease portfolio hypotension study DAVIDsTEA ...
Seekingalpha · 09/15 12:26
Avalo Therapeutics Priced 12.5M Share Public Offering of Common Stock @$2.20/Share
Avalo Therapeutics, Inc.
Benzinga · 09/15 09:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVTX. Analyze the recent business situations of Avalo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVTX stock price target is 6.50 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 67.06M
% Owned: 69.85%
Shares Outstanding: 96.01M
TypeInstitutionsShares
Increased
31
11.46M
New
11
251.88K
Decreased
18
3.80M
Sold Out
10
903.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.30%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Chairman/Chief Executive Officer/Director
Michael Cola
Chief Financial Officer/Treasurer
Schond Greenway
Chief Accounting Officer
Christopher Sullivan
Chief Scientific Officer
Garry Neil
Other
Jamie Harrell
Other
H. Jeffrey Wilkins
Lead Director/Independent Director
Suzanne Bruhn
Director
Joseph Miller
Independent Director
Steven Boyd
Independent Director
Phil Gutry
Independent Director
Gilla Kaplan
Independent Director
Magnus Persson
No Data
About AVTX
Avalo Therapeutics, Inc., formerly Cerecor, Inc., is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes targeted therapeutics for patients with clinical need in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates include AVTX-002, AVTX-007, AVTX-006 and AVTX 800 programs. Its AVTX-002 is an Anti-LIGHT mAb targeting immune-inflammatory diseases including acute respiratory distress syndrome (ARDS) and moderate-to-severe inflammatory bowel disease. Its AVTX-007 is an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases including multiple myeloma and Still’s disease. Its AVTX-006 is a dual mTORc1/c2 inhibitor targeting lymphatic malformations. Its AVTX 800 programs include AVTX-801, AVTX-802 and AVTX-803. Its AVTX 800 programs is a therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation (CDGs).

Webull offers kinds of Avalo Therapeutics Inc stock information, including NASDAQ:AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.